Rami Elghandour, president of arcelx (NASDAQ:ACLX)sold 89,916 shares for approximately $10.24 million on February 27, 2026, according to an SEC Form 4 filing.
|
Metric |
Worth |
|---|---|
|
Shares sold (direct) |
89,916 |
|
Transaction value |
10.2 million dollars |
|
Post-transaction actions (direct) |
276,051 |
|
Post-transaction actions (indirect) |
416,500 |
|
Post-transaction value (direct ownership) |
~$31.41 million |
Transaction value based on SEC Form 4 weighted average purchase price ($113.92); post-transaction value based on market close on February 27, 2026 ($113.79).
-
How does this transaction compare to Elghandour’s previous sales activity?
This sale of 89,916 shares is notably larger than its historical average sale size of 38,300 shares since January 2025. -
What impact does the sale have on the insider’s ownership profile?
Following the sale, Elghandour retains 276,051 shares directly owned and holds 416,500 shares indirectly through a marital trust, resulting in continued material exposure to Arcellx’s equity.
|
Metric |
Worth |
|---|---|
|
Price |
$113.79 |
|
Market capitalization |
6.65 billion dollars |
|
Net loss (TTM) |
-$228.93 million |
|
1 year price change |
75.55% |
*1-year price and yield are calculated using February 28, 2026 as the reference date.
Arcellx, Inc. is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer and other incurable diseases. The company primarily works with oncology healthcare providers and patients with difficult-to-treat cancers throughout the United States and select global markets.
Although ACLX stock prices have skyrocketed, the stock will soon be delisted as on February 23, 2026, the company announced that it would be acquired by Gilead Sciences (NASDAQ: DORADO)another global biopharmaceutical company. While there is no expected completion date for the transaction, the acquisition is estimated to be worth $7.8 billion, with Gilead purchasing Arcellx for $115 per share and a contingent value right of $5 per share.
The immunotherapy provider also recently achieved a breakthrough with one of its major clinical-stage projects, advancing its multiple myeloma treatment to Phase 2 development. Another of Arcellx’s greatest advances is an immunotherapy against blood cancer awaiting FDA approval, whose decision is expected in December 2026.
If the treatment is successful, it would be an important product in the healthcare space and a major revenue generator for Arcellx. However, with the merger on the way, it is difficult to say how much time investors have to trade shares before the company delists.